Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

Thrombospondins TSP-1 and TSP-2 are potent endogenous inhibitors of angiogenesis. They inhibit angiogenesis through direct effects on endothelial cell migration, proliferation, survival, and apoptosis and by antagonizing the activity of VEGF. Several of the membrane receptor systems and signal transduction molecules that mediate the effects of TSP-1 and TSP-2 have been elucidated. TSP-1 and TSP-2 exert their direct effects through CD36, CD47, and integrins. Recent data indicate that CD36 and β1 integrins collaborate to transmit the signals that are initiated by TSP-1 and TSP-2. Furthermore, these receptors appear to associate with VEGFR2 to form a platform for the integration of positive and negative signals for angiogenesis. Cross talk between pro- and antiangiogenic signal transduction pathways may enable TSP-1 and TSP-2 to inhibit angiogenesis by antagonizing survival pathways while also activating apoptotic pathways. CD36 and CD47 are both involved in the suppression of nitric oxide (NO). Advances in understanding of the molecular regulation of angiogenesis by TSP have paved the way for innovations in experimental treatment of cancers and will likely continue to offer vast avenues for discovery in other disease processes as well.

[1]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[2]  居軒 功 Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004 .

[3]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[4]  J. Lawler,et al.  Thrombospondin-based antiangiogenic therapy. , 2007, Microvascular research.

[5]  Yongji Wang,et al.  Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. , 2006, Microvascular research.

[6]  D. Wink,et al.  Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Kerbel,et al.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Wink,et al.  Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis , 2007, Clinical Cancer Research.

[9]  W. Sessa,et al.  Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Ribatti,et al.  Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors , 2010, The Journal of Biological Chemistry.

[11]  J. Lawler,et al.  Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model , 2005, Clinical Cancer Research.

[12]  Tracy T Batchelor,et al.  Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.

[13]  H. Dvorak,et al.  Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  J. Lawler,et al.  ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer , 2009, Molecular Cancer Therapeutics.

[15]  J. Lawler,et al.  Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. , 2007, Cancer letters.

[16]  I. Bernard-Pierrot,et al.  Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.

[17]  B. Griffin,et al.  Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. , 1993, Investigative ophthalmology & visual science.

[18]  P. Bornstein,et al.  Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. , 2007, Molecular biology of the cell.

[19]  D. Roberts,et al.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.

[20]  L. Liotta,et al.  Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.

[21]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[22]  P. Wen,et al.  Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.

[23]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[24]  D. Louis,et al.  Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors , 2010, Oncogene.

[25]  H. Groen,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Shibuya,et al.  Novel antiangiogenic pathway of thrombospondin‐1 mediated by suppression of the cell cycle , 2007, Cancer science.

[27]  R. Khosravi‐Far,et al.  A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. , 2009, Cancer research.

[28]  D. Mosher,et al.  Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses* , 2009, Journal of Biological Chemistry.

[29]  J. Henkin,et al.  The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. , 2010, Neoplasia.

[30]  S. Badylak,et al.  Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. , 2005, Journal of medicinal chemistry.

[31]  Julia Fukuyama,et al.  Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake* , 2007, Journal of Biological Chemistry.

[32]  J. Vacanti,et al.  Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. , 2002, Cancer research.

[33]  G. Demetri,et al.  Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Brown,et al.  Integrin-associated Protein Is a Receptor for the C-terminal Domain of Thrombospondin (*) , 1996, The Journal of Biological Chemistry.

[35]  D. Ingber,et al.  Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins , 2005, The Journal of cell biology.

[36]  T. Michel,et al.  Life history of eNOS: partners and pathways. , 2007, Cardiovascular research.

[37]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[38]  H. Rabb,et al.  Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. , 2005, The Journal of clinical investigation.

[39]  R. Tucker The thrombospondin type 1 repeat superfamily. , 2004, The international journal of biochemistry & cell biology.

[40]  M. Karin,et al.  c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1 , 2001, Oncogene.

[41]  M. Simons,et al.  Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2 , 2000, The Journal of Biological Chemistry.

[42]  R. Hynes,et al.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  O. Hudlická,et al.  Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. , 2005, American journal of physiology. Heart and circulatory physiology.

[44]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[45]  H. Izzedine,et al.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Fathallah-Shaykh,et al.  A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. , 2010, Archives of Neurology.

[48]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[49]  R. Silverstein,et al.  The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[50]  P. Bagavandoss,et al.  Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.

[51]  J. Lawler,et al.  Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. , 2001, Cancer research.

[52]  T Persson,et al.  A marker-free method to estimate joint centre of rotation by video image processing. , 1995, Computer methods and programs in biomedicine.

[53]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[54]  J. Coligan,et al.  Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. , 1978, The Journal of biological chemistry.

[55]  R. Hebbel,et al.  Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.

[56]  R. D'Amato,et al.  Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.

[57]  M. Iruela-Arispe Regulation of thrombospondin1 by extracellular proteases. , 2008, Current drug targets.

[58]  M. Danks,et al.  Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.

[59]  O. Volpert,et al.  Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. , 1999, Molecular pharmacology.

[60]  R. Jain,et al.  Role of eNOS in neovascularization: NO for endothelial progenitor cells. , 2004, Trends in molecular medicine.

[61]  G. Lang,et al.  Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. , 2009, Critical reviews in oncology/hematology.

[62]  P. Bornstein,et al.  Enhanced Angiogenesis and Reduced Contraction in Thrombospondin-2–null Wounds Is Associated With Increased Levels of Matrix Metalloproteinases-2 and −9, and Soluble VEGF , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[63]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[64]  J. Lawler,et al.  The cell biology of thrombospondin-1. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[65]  J. Lawler,et al.  Internalization but not binding of thrombospondin‐1 to low density lipoprotein receptor‐related protein‐1 requires heparan sulfate proteoglycans , 2004, Journal of cellular biochemistry.

[66]  E. D. de Vries,et al.  Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. , 2006, European journal of cancer.

[67]  J. Lawler,et al.  Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1) , 2007, Journal of cellular physiology.

[68]  J. Ingle,et al.  A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma , 2007, American journal of clinical oncology.

[69]  R. Kerbel,et al.  Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy , 2005, Clinical Cancer Research.

[70]  D. Wink,et al.  CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1* , 2006, Journal of Biological Chemistry.

[71]  Thomas Hawighorst,et al.  CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo , 2010, Breast Cancer Research and Treatment.

[72]  J. Lawler,et al.  Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets , 2008, Diabetes.

[73]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[74]  O. Volpert,et al.  Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium–derived factor , 2002, Nature Medicine.

[75]  H. Krutzsch,et al.  Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[76]  Erwin G. Van Meir,et al.  Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. , 2003, The American journal of pathology.

[77]  Ralph Weissleder,et al.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy , 2009, Proceedings of the National Academy of Sciences.

[78]  J. Henkin,et al.  ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis , 2007, Cancer biology & therapy.

[79]  A. Stopeck,et al.  A phase 1 trial of 2 dose schedules of ABT‐510, an antiangiogenic, thrombospondin‐1‐mimetic peptide, in patients with advanced cancer , 2008, Cancer.

[80]  G. Tuszynski,et al.  Matrix-bound thrombospondin promotes angiogenesis in vitro , 1994, The Journal of cell biology.

[81]  M. Iruela-Arispe,et al.  Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.

[82]  C. Dinney,et al.  Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics , 2002, International journal of cancer.

[83]  B. Banas,et al.  Identification of Novel β1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1* , 2004, Journal of Biological Chemistry.

[84]  O. Volpert,et al.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. , 2008, Current drug targets.

[85]  R K Jain,et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  A. Joachimiak,et al.  Crystal structure of the TSP-1 type 1 repeats , 2002, The Journal of cell biology.

[87]  B. Hopkins,et al.  Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. , 2009, American journal of physiology. Heart and circulatory physiology.

[88]  D. Wink,et al.  Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[89]  R. Figlin,et al.  Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[90]  S. Donnini,et al.  Role of nitric oxide in the modulation of angiogenesis. , 2003, Current pharmaceutical design.

[91]  D. Wink,et al.  Blockade of Thrombospondin-1-CD47 Interactions Prevents Necrosis of Full Thickness Skin Grafts , 2008, Annals of surgery.

[92]  M. Alessio,et al.  ©2005 FASEB The FASEB Journal express article 10.1096/fj.05-3697fje. Published online July 21, 2005. Identification of CD36 molecular features required for its in vitro angiostatic activity , 2022 .

[93]  C. Legrand,et al.  A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. , 2002, Matrix biology : journal of the International Society for Matrix Biology.